MetaCap

Cypherpunk Technologies (CYPH) vs Pyxis Oncology (PYXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cypherpunk Technologies (CYPH) has outperformed Pyxis Oncology (PYXS) over the past year, losing 38.2% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -94.4% for CYPH. Pyxis Oncology is the larger company by market cap ($216.5 million vs $210.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYPH-38.16%PYXS-62.29%
+89%+1%-86%
Nov 21, 20251 yearNov 20, 2026
CYPH-93.79%PYXS-85.99%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYPH versus PYXS key metrics
MetricCYPHPYXS
Share price$1.41$1.81
Market cap$210.15M$216.49M
1-day change-18.02%+7.74%
YTD return+21.55%+57.39%
1-year return-38.16%-62.29%
5-year return-94.45%-85.90%
P/E ratio (TTM)0.67—
EPS (TTM)$2.09$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.86M
Revenue growth (YoY)—-14.17%
Net income (latest FY)$4.82M$-79.62M
Gross margin—82.77%
Operating margin—-609.18%
Net margin—-574.55%
52-week high$4.19$5.55
52-week low$0.491$1.03
Distance from 52-week high-66.35%-67.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+254.61%+354.14%
Average volume15.42M1.06M
Shares outstanding149.04M119.61M
Employees656
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYPH has outperformed PYXS by 24.1 percentage points over the past year.

About Cypherpunk Technologies

CYPH stock →

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

CYPH vs PYXS FAQ

Which is bigger, Cypherpunk Technologies or Pyxis Oncology?

Pyxis Oncology (PYXS) is larger, with a market capitalization of $216.49M compared with $210.15M for Cypherpunk Technologies (CYPH).

Which stock has performed better over the past year, CYPH or PYXS?

CYPH returned -38.16% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Cypherpunk Technologies and Pyxis Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons